Abstract
Induction of the transcription factor ΔFosB was studied to examine neurochemical adaptations produced by repeated opiate administration. The mechanism of this induction was also investigated. The 35- to 37-kDa isoforms of ΔFosB, also referred to as the chronic Fras, were measured in the nucleus accumbens, caudate putamen, and frontal cortex of male Sprague-Dawley rats after either an acute injection of morphine or an escalating dosing schedule of morphine for 10 days. Heroin was also tested to determine whether the findings extend to other opiates. Results from Western blot analysis using an anti-fosB antibody demonstrate that 10-day intermittent escalating dose morphine produced a significant increase in ΔFosB-immunoreactivity in the nucleus accumbens, caudate putamen and frontal cortex, whereas a single injection of morphine had no effect on Fra immunoreactivity. Heroin administered twice daily for 10 days by an intermittent escalating dose schedule also induced ΔFosB in the caudate putamen, but not in the nucleus accumbens or frontal cortex. Daily pretreatment with the selective D1-like dopamine receptor antagonist SCH 23390 [R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride] significantly blocked morphine-induced ΔFosB induction in the nucleus accumbens and caudate putamen, but not in the frontal cortex. These results demonstrate that morphine-induced ΔFosB up-regulation in the striatum, but not in the frontal cortex, is modulated by D1 dopamine receptors, suggesting that the mechanisms involved in the up-regulation of these chronic Fras by morphine is brain region-specific.
Footnotes
-
This work was supported by National Institutes of Health/National Institute on Drug Abuse Grants T32 DA07237 (E.M.U.), F31 DA017421 (D.L.M.), and P30 DA13429 (M.W. Adler).
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org. doi:10.1124/jpet.105.083410.
-
ABBREVIATIONS: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; GluR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor; Cdk5, cyclin-dependent kinase-5; SCH 23390, R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride; ANOVA, analysis of variance; MK-801, dizocilpine maleate; GYKI-52466, 1-(4-aminophenyl)-4-methyl-7,8-methyl-enedioxy-5H-2,3-benzodiazepine hydrochloride.
- Received January 10, 2005.
- Accepted March 15, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|